-
公开(公告)号：US20240360234A1
公开(公告)日：2024-10-31
申请号：US18657550
申请日：2024-05-07
Applicant: Nkarta, Inc.
Inventor： James Barnaby Trager , Alexandra Leida Liana Lazetic , Ivan Chan , Chao Guo , Katherine Jamboretz
IPC: C07K16/28 , C07K14/705 , C07K14/715 , C07K14/725 , C12N15/90
CPC classification number: C07K16/2875 , C07K14/7051 , C07K14/70578 , C07K14/7155 , C12N15/907 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2310/20 , C12N2800/80
Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.
-
公开(公告)号：US12129291B2
公开(公告)日：2024-10-29
申请号：US18335477
申请日：2023-06-15
Applicant: Yamaguchi University , National Cancer Center , Noile-Immune Biotech, Inc.
Inventor： Koji Tamada , Yukimi Sakoda , Tetsuya Nakatsura , Keigo Saito
IPC: C07K16/18 , C07K14/54 , C07K14/725 , C07K16/30 , C12N5/078 , C12N5/0783 , G01N33/68
CPC classification number: C07K16/18 , C07K14/5418 , C07K14/7051 , C07K16/303 , C12N5/0634 , C12N5/0636 , G01N33/68 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2319/02 , C07K2319/03
Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
-
公开(公告)号：US20240352123A1
公开(公告)日：2024-10-24
申请号：US18715007
申请日：2022-12-02
Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION , UNIVERSITY OF MARYLAND BALTIMORE, OFFICE OF TECHNOLOGY TRANSFER
Inventor： Tim C. Luetkens , Erica Vander Mause , Djordje Atanackovic
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , C07K14/705 , C07K14/725 , C07K14/73
CPC classification number: C07K16/2803 , A61K39/3955 , A61K39/4611 , A61K39/4631 , A61K39/464411 , A61K45/06 , A61P35/00 , C07K14/70503 , C07K14/7051 , C07K14/70514 , C07K14/70521 , C07K14/70578 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/42
Abstract: Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD229 binding domain is a variant CD229 antigen binding domain. Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD229 antigen binding domain comprises the sequence of SEQ ID NO:134, SEQ ID NO:53, or SEQ ID NO:84. Disclosed are methods of using the CAR polypeptides or antibodies comprising the same CD229 antigen binding domain as the CAR polypeptides.
-
4.发明公开
公开(公告)号：US20240352085A1
公开(公告)日：2024-10-24
申请号：US18602534
申请日：2024-03-12
Inventor： Qiuhong LI , Mohan RAIZADA
IPC: C07K14/575 , A61K35/00 , A61K35/74 , A61K35/741 , A61K35/747 , A61K45/06 , A61K48/00 , A61P3/00 , A61P3/10 , A61P9/12 , A61P27/02 , A61P29/00 , C07K7/14 , C07K14/195 , C07K14/28 , C07K14/47 , C07K19/00 , C12N1/00 , C12N9/48
CPC classification number: C07K14/575 , A61K35/74 , A61K35/741 , A61K35/747 , A61K45/06 , A61P3/00 , A61P3/10 , A61P9/12 , A61P27/02 , A61P29/00 , C07K7/14 , C07K14/195 , C07K14/28 , C07K14/47 , C07K19/00 , C12N1/00 , C12N9/485 , A61K2035/115 , A61K48/00 , C07K2319/02 , C07K2319/50 , C07K2319/60
Abstract: Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.
-
公开(公告)号：US20240350606A1
公开(公告)日：2024-10-24
申请号：US18665046
申请日：2024-05-15
Applicant: DUKE UNIVERSITY , THE JOHNS HOPKINS UNIVERSITY
Inventor： YOU-WEN HE , HEQIANG SUN , THOMAS AUGUST , JUN LIU , YADONG WEI
IPC: A61K39/00 , A61K39/245 , A61P35/00 , C07K14/005 , C07K14/47 , C12N15/85
CPC classification number: A61K39/001192 , A61K39/0008 , A61K39/001104 , A61K39/001106 , A61K39/001109 , A61K39/001184 , A61K39/001186 , A61K39/245 , A61P35/00 , C07K14/005 , C07K14/4738 , C07K14/4748 , C12N15/85 , A61K2039/5154 , A61K2039/53 , A61K2039/585 , C07K2319/01 , C07K2319/02 , C07K2319/06 , C07K2319/40 , C12N2710/16134 , C12N2800/22 , C12N2840/203
Abstract: Vaccine design, polycistronic vaccine constructs, compositions, and methods comprising nucleic acids (DNA, RNA), peptides, proteins and derivatives thereof, including cells and cell-lines, for enhanced antigen-specific vaccination.
-
公开(公告)号：US20240350546A1
公开(公告)日：2024-10-24
申请号：US18686868
申请日：2022-08-31
Applicant: The Texas A&M University System , The Research Institute at Nationwide Children's Hospital
Inventor： Xiaotong Song , Ruoning Wang , Abhijit Sarkar , Yue Hu
IPC: A61K35/17 , A61K39/00 , A61P35/00 , C07K14/55 , C07K14/705 , C12N5/0783 , C12N9/78
CPC classification number: A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/4644 , A61P35/00 , C07K14/55 , C07K14/70596 , C12N5/0636 , C12N9/78 , C07K2317/622 , C07K2319/02 , C07K2319/30 , C12Y305/04004
Abstract: The present application provides methods and compositions for treating cancers using a CAR T cell therapy platform. Also provided are methods and use of the CAR T cells for treating diseases and conditions, such as cancer, and in particular any disease or condition associated with elevated adenosine or other associate marker.
-
公开(公告)号：US20240350545A1
公开(公告)日：2024-10-24
申请号：US18683208
申请日：2022-08-18
Applicant: LEGEND BIOTECH IRELAND LIMITED
Inventor： Yanliang ZHU , Qingling JIANG , Zhongyuan TU , Yafeng ZHANG , Shu WU , Xiaohu FAN
IPC: A61K35/17 , A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/86
CPC classification number: A61K35/17 , A61K39/4611 , A61K39/4613 , A61K39/4631 , A61K39/4632 , A61K39/464412 , A61K39/464417 , A61K39/464424 , A61K39/464429 , A61K39/464474 , A61P35/00 , C07K14/7051 , C07K14/70596 , C07K16/2803 , C07K16/2851 , C07K16/2863 , C07K16/2887 , C07K16/303 , C12N5/0638 , C12N5/0646 , C12N15/86 , A61K2239/13 , C07K2317/569 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N2510/00 , C12N2740/15043
Abstract: The present application provides modified immune cells that express TLR receptors. In some embodiments, the modified immune cell further comprises an engineered receptor such as a chimeric antigen receptor (CAR). The present application also provides methods and pharmaceutical compositions for cancer treatment using the modified immune cells described herein.
-
公开(公告)号：US12121539B2
公开(公告)日：2024-10-22
申请号：US15759046
申请日：2016-09-10
Applicant: BIOSCEPTRE (AUST) PTY LTD
Inventor： Justin Taylor Coombs , Simon Charles Barry , Timothy John Sadlon
IPC: A61K35/17 , C07K14/705 , C07K14/715 , C07K14/725 , C07K14/735 , C07K16/28 , C12N5/0786 , C07K19/00
CPC classification number: A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70535 , C07K14/70578 , C07K14/715 , C07K16/28 , C12N5/0645 , C07K19/00 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/60
Abstract: The present invention relates to chimeric antigen receptors (CARs) directed to cells expressing a dysfunctional or non-functional P2X purinoceptor 7 receptor. Further provided are methods of targeting neoplastic cells and tumours expressing a dysfunctional or non-functional P2X purinoceptor 7 receptor and methods of treating and preventing cancer is a subject.
-
公开(公告)号：US20240343785A1
公开(公告)日：2024-10-17
申请号：US18611706
申请日：2024-03-21
Applicant: Jinan University
Inventor： Sen Yan , Shihua Li , Caijuan Li , Xiaojiang Li , Yingqi Lin
IPC: C07K16/18 , A61K38/00 , C07K14/705
CPC classification number: C07K16/18 , C07K14/70596 , A61K38/00 , C07K2317/80 , C07K2319/02
Abstract: Disclosed are an intracellular antibody (intrabody) and a preparation method and a use thereof. The intrabody includes a fragment of the variable region of the heavy chain (VH) of a monoclonal antibody that recognizes mutant huntingtin (mHTT) and a signal sequence of lysosome-associated membrane protein I (LAMP1). The VH fragment includes an amino acid sequence as shown in any one of SEQ. ID NO. 1-3. The intrabody described in this application possesses a bidirectional recognition function, enabling it to bind to and recognize mHTTs as well as specifically recognize lysosomes, thereby realizing the targeted degradation of mutant proteins and improving the degradation efficiency of the mutant proteins.
-
10.发明公开
公开(公告)号：US20240342310A1
公开(公告)日：2024-10-17
申请号：US18625283
申请日：2024-04-03
Applicant: University of Virginia Patent Foundation , Sun Yat Sen Memorial Hospital, Sun Yat Sen University
Inventor： Hui Li , Qiong Wang , Hai Huang
CPC classification number: A61K48/005 , A61P35/00 , C07K14/47 , A61K38/00 , C07K2319/02
Abstract: Disclosed herein are peptides and peptidomimetics that inhibit the progression of prostate cancer by up-regulating FLRT3. Also disclosed are methods for treating an FLRT3-attenuated cancer in a subject that involve administering to the subject the disclosed polypeptide or peptidomimetic or a polynucleotide encoding the disclosed peptide.
